Sara Moore,Chloé Thabet,Paul Wheatley-Price
Sara Moore
Introduction: Medical assistance in dying (MAiD) was legalized in Canada in 2016. Cancer accounts for 60% to 65% of MAiD cases. Lung cancer, the most common cause of cancer death, is expected to makeup a large number of M...
Prognostic Stratification According to Size and Dominance of Radiologic Solid Component in Clinical Stage IA Lung Adenocarcinoma [0.03%]
基于影像学实性成分的大小和优势程度对临床ⅠA期肺腺癌进行预后分层分析
Masayuki Nakao,Katsunori Oikado,Yoshinao Sato et al.
Masayuki Nakao et al.
Introduction: Although several studies have investigated the prognostic significance of the radiographic appearance of stage IA lung adenocarcinoma, the prognostic impact of solid component size or consolidation-to-tumor ...
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs [0.03%]
ROS1和MYC扩增是不同代ALK酪氨酸激酶抑制剂的协同耐药机制：晚期非小细胞肺癌临床及前期证据简报
Roberta Minari,Samuel Valentini,Denise Madeddu et al.
Roberta Minari et al.
Introduction: ALK tyrosine kinase inhibitors (TKIs) are the standard treatment for advanced ALK-positive NSCLC. Nevertheless, drug resistance inevitably occurs. Here, we report a case of a patient with metastatic ALK-posi...
Composite Clonal Analysis Reveals Transition of NSCLC Subtypes Through Accumulation of Gene Mutations: A Case Report [0.03%]
复合克隆分析揭示通过基因突变累积导致的非小细胞肺癌亚型转变：病例报告
Takahiro Ando,Hidenori Kage,Aya Shinozaki-Ushiku et al.
Takahiro Ando et al.
We analyzed an EGFR-mutated lung cancer with a pathologic diagnosis of combined large cell neuroendocrine carcinoma with mixed adenocarcinoma subtypes. Targeted next-generation sequencing of each component suggested that mutations in RB1, T...
"Real" Tumor-Spread Through Air Spaces of Lung Adenocarcinoma Presented Intrapulmonary Metastases Through Bronchiole Air Spaces: A Case Report [0.03%]
肺腺癌经支气管管道内播散致肺癌内瘤转移1例报告
Sawako Kaku,Noriko Motoi,Hirokazu Watanabe et al.
Sawako Kaku et al.
Here, we report a rare case of lung adenocarcinoma with intrapulmonary metastases that have "spread through air spaces" (STAS) by means of the alveoli and bronchioles. The peripheral intrapulmonary metastases were exhibiting pure ground-gla...
Real-World Treatment Patterns and Outcomes Among Patients With Metastatic NSCLC Previously Treated With Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Inhibitors [0.03%]
程序性死亡配体-1抑制剂经治的转移性非小细胞肺癌患者的治疗模式和结果
Savreet Bains,Anu Kalsekar,Katayoun I Amiri et al.
Savreet Bains et al.
Introduction: Programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors are standard-of-care treatment for metastatic NSCLC (mNSCLC). Intolerance to treatment/disease progression warrants additio...
Thoracic Radiotherapy in Limited-Stage SCLC-a Population-Based Study of Patterns of Care in Norway From 2000 Until 2018 [0.03%]
2000年至2018年挪威限制期小细胞肺癌的胸部放射治疗：基于人口的研究护理模式
Gustav Graabak,Bjørn Henning Grønberg,Marie Søfteland Sandvei et al.
Gustav Graabak et al.
Introduction: Twice-daily (BID) thoracic radiotherapy (TRT) of 45 Gy per 30 fractions is recommended for limited-stage (LS) SCLC, but most patients are treated with once-daily (OD) schedules owing to toxicity concerns and...
A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC [0.03%]
帕博利珠单抗联合化疗治疗非鳞状非小细胞肺癌的疗效和安全性真实世界研究
Daichi Fujimoto,Satoru Miura,Kenichi Yoshimura et al.
Daichi Fujimoto et al.
Introduction: The real-world effectiveness of combination treatment with cytotoxic chemotherapy and programmed cell death protein-1 or programmed death-ligand 1 inhibitor for NSCLC, especially for the elderly (aged ≥75 y...
Effects of Ethnicity on Outcomes of Patients With EGFR Mutation-Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection [0.03%]
种族对EGFR突变阳性NSCLC患者接受EGFR酪氨酸激酶抑制剂和手术治疗预后的影响
Mike R Sung,Pascale Tomasini,Lisa W Le et al.
Mike R Sung et al.
Introduction: In addition to the higher prevalence of EGFR mutations found among lung cancer cases in East Asian patients, it is unclear whether there are differences in treatment outcomes by ethnicity-that is, East Asian...
Cytokine Release Syndrome and Immune-Related Pneumonitis Associated With Tumor Progression in a Pulmonary Pleomorphic Carcinoma Treated With Nivolumab Plus Ipilimumab Treatment: A Case Report [0.03%]
一例肺多形细胞癌患者接受纳武利尤单抗联合伊匹木尼亚治疗后出现细胞因子释放综合征和免疫相关性肺炎的病例报告
Kei Kunimasa,Takako Inoue,Katsunori Matsueda et al.
Kei Kunimasa et al.
Effective control of severe immune-related adverse events, including cytokine release syndrome (CRS), is essential for the success of immunotherapy. We present a case of a granulocyte colony-stimulating factor-producing pleomorphic lung car...